Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17931 (
galectin-3
)
2,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The development of high-throughput screening (HTS) assays with increased sensitivity for the identification of potent and selective inhibitors of galectins has been hampered by the weak binding affinities between galectins and their carbohydrate ligands. To circumvent this obstacle, we have developed an AlphaScreen assay for a 384-well plate format in a competitive binding configuration for discovery of new inhibitors of
galectin-3
. His-tagged
galectin-3
was bound to nickel chelate acceptor beads, whereas biotinylated asialofetuin (biotin-ASF), a
galectin-3
nanomolar binding partner, was bound to streptavidin-coated donor beads. Inhibitors of the carbohydrate-galectin interaction lead to a reduction of the AlphaScreen signal by competing with the biotin-
ASF
. The obtained IC50 values for known carbohydrate ligands of
galectin-3
are in good agreement with the Kd values reported and measured for
galectin-3
by isothermal titration calorimetry (ITC). Thus, the developed AlphaScreen assay in a competitive binding configuration offers several advantages over the existing screening assays for inhibitors of glycan-lectin interactions. In addition, the assay format for the
galectin-3
/
ASF
pair could be easily applied in screening for glycan- and/or small molecule-based inhibitors of other members of the galectin family.
...
PMID:Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan-lectin interactions. 2368 52